Brand Name(s): Simulect
CAS nš: 152923-56-3
(ba sil ik si mab)
About Basiliximab
This new site is dedicated exclusively to basiliximab.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about basiliximab on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total basiliximab experience!
Why is this medication prescribed?
Basiliximab belongs to a group of medicines known as immunosuppressive agents. It is used to lower the body's natural immunity in patients who receive kidney transplants.
When a patient receives a kidney transplant, the body's white blood cells will try to get rid of (reject) the transplanted kidney. This medicine works by preventing the white blood cells from getting rid of the transplanted kidney. The effect of this medicine on the white blood cells may also reduce the body's ability to fight infections.
Latest News
Antibody Reduces Rejection in High-risk Kidney Transplants
Nearly 70 percent of kidney transplant patients get short-term drug therapy initially administered...
[more]Induction therapy post-heart transplantation with basiliximab is safer than muromonab
In a recent heart transplantation study, induction therapy with basiliximab was safer and better...
[more]Cerimon licenses Novartis bowel disease drug
Cerimon Pharmaceuticals has licensed the exclusive worldwide rights from Novartis Pharma to develop...
[more]Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect(R) for the Treatment of Inflammatory Bowel Disease
South San Francisco, Calif. -- Cerimon Pharmaceuticals, Inc. announced today that it has licensed...
[more]Basiliximab Plus Tacrolimus Reduce Liver Transplant Rejection, Increase Survival
Basiliximab in a tacrolimus-based immunosuppressive regimen is effective in reducing incidences of...
[more]